Wednesday, July 8, 2026

Patent intelligence · US

US 11318091

Gastroretentive dosage forms for sustained drug delivery

granted A61KA61K31/195A61K31/198A61K31/403
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 16
Applicant portfolio 32
Patent details — US 11318091
Jurisdiction
US
Status
granted
Grant date
May 3, 2022
Expiration
Apr 28, 2042
Claims
20
CPC classes
A61K, A61K31/195, A61K31/198, A61K31/403
View on Google Patents ↗

Quick answer

US 11318091 (Gastroretentive dosage forms for sustained drug delivery) is held by Amneal Complex Products Research LLC. Status: granted. Granted May 3, 2022. Expires Apr 28, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61K, A61K31/195, A61K31/198, A61K31/403, A61K31/404, A61K31/4166

More from Amneal Complex Products Research LLC

Related pharmaceutical patents in our USPTO index.

  1. US 12383522

    Baclofen formulations and methods of minimizing patient exposure to metabolite variations

    AMNEAL PHARMACEUTICALS LLC · Expires Aug 7, 2045

    granted
  2. US 12370163

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Expires Jul 24, 2045

    granted
  3. US 12303482

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Expires May 15, 2045

    granted
  4. US 12303481

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Expires May 15, 2045

    granted
  5. US 12295931

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Expires May 8, 2045

    granted
  6. US 12263149

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Expires Mar 27, 2045

    granted
  7. US 12263148

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Expires Mar 27, 2045

    granted
  8. US 12233166

    Extended release compositions comprising pyridostigmine

    Amneal Complex Products Research LLC · Expires Feb 20, 2045

    granted

Frequently asked questions

What is US patent 11318091?

US 11318091 (Gastroretentive dosage forms for sustained drug delivery) is held by Amneal Complex Products Research LLC. Status: granted. Granted May 3, 2022. Expires Apr 28, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11318091?

Amneal Complex Products Research LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 32 pharmaceutical patents for this assignee.

When does US 11318091 expire?

Our index shows an expiration date of Apr 28, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.